ReviewBiomolecules2026
Chemokine Networks in Blood-Brain Barrier Regulation: Bidirectional Mechanisms, Clinical Translation, and Precision Therapeutic Prospects.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of CXCL12 Diagnostic Performance in Tick-Borne Encephalitis and Other Central Nervous System Infections.International journal of molecular sciences · 2026Article
- CYP46A1 activation by low-dose efavirenz uncovers the link between brain cholesterol metabolism, energetics, and vasculature.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The blood-brain barrier (BBB), a core component of the neurovascular unit (NVU), meticulously regulates material exchange between the blood and brain parenchyma, serving as a critical barrier for maintaining the homeostasis of the central nervous system (CNS). Neuroinflammation, a pivotal response of the CNS to injury and disease, can disrupt NVU homeostasis when excessive or persistent, acting as a core pathogenic driver of various intractable neurological disorders. Chemokines, as key signaling molecules guiding the directional migration of immune cells, form the central hub mediating the dynamic regulation of neuroinflammation and the BBB. However, existing studies mostly focus on single disease systems or chemokine families, neglecting the bidirectional heterogeneity of different chemokine axes in BBB regulation and the common regulatory rules across diseases, while lacking systematic exploration of clinical translation challenges caused by the redundancy and spatiotemporal heterogeneity of the chemokine network. This review systematically clarifies the bidirectional regulatory effects of the core axes of the three major chemokine families (e.g., CCL2/CCR2, CXCL12/CXCR4, CX3CL1/CX3CR1) on the BBB. For the first time, we integrate a multi-dimensional regulatory model based on concentration, location, and time to analyze their molecular mechanisms and regulatory heterogeneity in promoting BBB disruption under pathological conditions versus mediating barrier repair and neuroprotection under specific spatiotemporal conditions. Combined with advancements in cutting-edge models such as microfluidic chips, we discuss the clinical translation progress of chemokine research, including potential biomarkers and targeted therapeutic strategies, and propose precise breakthrough paths for the two core challenges of network redundancy and spatiotemporal heterogeneity. Finally, we construct a complete research framework for chemokine-mediated regulation of NVU homeostasis, providing novel insights and directions for restoring BBB function and treating intractable neurological diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.